P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT
Inhibition of mammalian target of rapamycin: The janus face of immunosuppression?
β Scribed by Christopher Soll; Pierre-Alain Clavien
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 106 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3βkinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signalβtransduction pathways, is involved in the coupling of g
## Abstract Curcumin (diferuloylmethane), a polyphenol natural product of the plant __Curcuma longa__, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Here we show that curcumin inhibited growth of rhabdomyosar